AI
| Followers | 843 |
| Posts | 122814 |
| Boards Moderated | 10 |
| Alias Born | 09/05/2002 |
Thursday, August 09, 2018 5:04:43 PM
ENTA has disclosed the royalty-rate tiers for the 50% of Mavyret sales attributable to Glecaprevir (ENTA’s HCV protease inhibitor):
https://www.sec.gov/Archives/edgar/data/1177648/000156459018021062/enta-10q_20180630.htm (page 12):
https://www.sec.gov/Archives/edgar/data/1177648/000156459018021062/enta-10q_20180630.htm (page 12):
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
